Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: Intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol, SULT1A3 substrate

Journal of Pharmaceutical Sciences

Volumn 97, Issue 12, 2008, Pages 5471-5476

  Mizuma, Takashi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Bioavailability; First pass metabolism; Intestinal metabolism; Metabolic clearance; Phase II metabolism

Indexed keywords

SALBUTAMOL; SULFOTRANSFERASE 1A1; SULT1A3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; ENZYME SUBSTRATE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIVER METABOLISM; LUNG PARENCHYMA; MATHEMATICAL COMPUTING; SULFATION;

EID: 57349152452     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21363     Document Type: Article

References (11)

1. Rowland M, Tozer TM. 1995. Clinical pharmacokinetics. Philadelphia: Williams & Willkins. pp. 119-136.
2. Mizuma T. 2002. Kinetic impact of presystemic intestinal metabolism on drug absorption: Experiment and data analysis for the prediction of in vivo absorption from in vitro data. Drug Metab Pharmacokinet 17:496-506.
3. Mizuma T, Tsuji A, Hayashi M. 2004. Does the well-stirred model assess the intestinal first-pass effect well? J Pharm Pharmacol 56:1597-1599.
4. Pacifici GM, Santi CD, Mussi A, Ageletti CA. 1996. Interindividual variability in the rate of salbutamol sulphation in the human lung. Eur J Clin Pharmacol 49:299-303.
5. Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP. 1986. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 22:587-593.
6. Pang KS, Rowland M. 1977. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:655-680.
7. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
8. Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, Muraro GB. 1988. Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 18:849-856.
9. Mizuma T, Kawashima K, Sakai S, Sakaguchi S, Hayashi M. 2005. Differentiation of organ availability by sequential and simultaneous analyses: Intestinal conjugative metabolism impacts on intestinal availability in humans. J Pharm Sci 94:571-575.
10. Vietri M, Pietrabissa A, Mosca F, Rane A, Pacific GM. 2001. Human adult and foetal liver sulphotransferases: Inhibition by mefenamic acid and salicylic acid. Xenobiotica 31:153-161.
11. Glatt H, Boeing H, Engelke CE, Ma L, Kuhlow A, Pabel U, Pomplun D, Teubner W, Meinl W. 2001. Human cytosolic sulphotransferases: Genetics, characteristics, toxicological aspects. Mutat Res 482:27-40.